This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
CCXI 주식 개요
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.
ChemoCentryx, Inc. 경쟁사
가격 내역 및 성능
| 과거 주가 | |
|---|---|
| 현재 주가 | US$51.99 |
| 52주 최고치 | US$52.00 |
| 52주 최저치 | US$14.95 |
| 베타 | 1.23 |
| 11개월 변경 | 0.41% |
| 3개월 변경 사항 | 134.51% |
| 1년 변경 사항 | 50.39% |
| 33년 변화 | 558.10% |
| 5년 변화 | 642.71% |
| IPO 이후 변화 | 372.64% |
최근 뉴스 및 업데이트
ChemoCentryx shareholders approve $4.7B merger with Amgen
Oct 18ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
Aug 09Recent updates
ChemoCentryx shareholders approve $4.7B merger with Amgen
Oct 18ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
Aug 09ChemoCentryx: Revisiting The Investment Case
Jun 21ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Jun 06
ChemoCentryx: Good Post-Approval Performance, But Needs More Time
Mar 03ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Feb 11Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week
Jan 21Checking In On ChemoCentryx
Dec 15Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?
Oct 09ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way
Sep 29ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends
Aug 24Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook
Aug 11ChemoCentryx: CRL Less Likely
Jul 25ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price
Jul 11ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jun 15ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress
Jun 08ChemoCentryx: CRL Likely
May 09ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action
May 07Chemocentryx shares plunge 47% as FDA report identifies concerns with vasculitis candidate
May 04When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?
Mar 03ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 04
ChemoCentryx: Great Drug, Good Prospects, Uncomfortable Stock Price
Jan 14Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?
Dec 31Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)
Dec 23ChemoCentryx's avacopan flunks mid-stage study in rare kidney disease study
Dec 21Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?
Dec 13Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?
Nov 22ChemoCentryx, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 10주주 수익률
| CCXI | US Biotechs | US 마켓 | |
|---|---|---|---|
| 7D | 0.1% | 3.7% | 5.7% |
| 1Y | 50.4% | 29.2% | 36.9% |
수익률 대 산업: CCXI 지난 1년 동안 29.2 %를 반환한 US Biotechs 산업을 초과했습니다.
수익률 대 시장: CCXI 지난 1년 동안 36.9 %를 반환한 US 시장을 초과했습니다.
가격 변동성
| CCXI volatility | |
|---|---|
| CCXI Average Weekly Movement | 31.3% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 3.0% |
안정적인 주가: CCXI 의 주가는 지난 3개월 동안 변동성이 심했습니다.
시간에 따른 변동성: CCXI 의 주간 변동성은 지난 1년 동안 18% 에서 31% 로 증가했습니다.
회사 소개
| 설립 | 직원 | CEO | 웹사이트 |
|---|---|---|---|
| 1996 | 178 | n/a | www.chemocentryx.com |
ChemoCentryx, Inc. 기본 사항 요약
| CCXI 기본 통계 | |
|---|---|
| 시가총액 | US$3.74b |
| 수익(TTM) | -US$133.09m |
| 수익(TTM) | US$37.28m |
100.3x
P/S 비율-28.1x
P/E 비율CCXI 주가가 과대평가되어 있나요?
공정 가치 및 가치 분석 보기수익 및 수익
| CCXI 손익 계산서(TTM) | |
|---|---|
| 수익 | US$37.28m |
| 수익 비용 | US$71.86m |
| 총 이익 | -US$34.58m |
| 기타 비용 | US$98.51m |
| 수익 | -US$133.09m |
최근 보고된 수익
Jun 30, 2022
다음 수익 날짜
n/a
| 주당 순이익(EPS) | -1.85 |
| 총 마진 | -92.76% |
| 순이익 마진 | -357.01% |
| 부채/자본 비율 | 10.5% |
CCXI 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기